Literature DB >> 7513608

Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer.

W M Stadler1, J Sherman, S K Bohlander, D Roulston, M Dreyling, D Rukstalis, O I Olopade.   

Abstract

The loss of DNA sequences on chromosomal bands 9p21-22 has been documented in a variety of malignancies including leukemias, gliomas, lung cancers, and melanomas. Because of the high incidence of monosomy 9 detected by both cytogenetics and loss of heterozygosity studies in bladder cancer, we examined seven bladder cancer cell lines for deletions in this region. Using seven DNA probes that span the region of 9p21-22 as well as a functional assay for methylthioadenosine phosphorylase (MTAP), which maps to 9p21, we found four cell lines that had small homozygous deletions. These deletions map centromeric to the interferon (IFN) gene cluster and telomeric to D9S171. Only one of the cell lines with deletions had a cytogenetically evident lesion in this chromosomal region. Preliminary loss of heterozygosity studies with 10 primary bladder cancer specimens using 10 markers spanning chromosome 9 revealed loss of heterozygosity at the IFN locus with retention of heterozygosity with more centromeric 9p markers and all informative 9q markers in the tumor of one patient. These data suggest that loss of a tumor suppressor gene on 9p21-22, which may represent a general pathway of oncogenesis, is important in bladder cancer development.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513608

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  The prognostic value of FGFR3 mutational status for disease recurrence and progression depends on allelic losses at 9p22.

Authors:  Guillaume Ploussard; Hany Soliman; Francis Dubosq; Paul Méria; Jérôme Vérine; François Desgrand-Champs; Hugues Dethé; Pierre Mongiat-Artus
Journal:  Am J Cancer Res       Date:  2011-03-11       Impact factor: 6.166

Review 2.  Genetics of bladder cancer.

Authors:  K K Saran; D Gould; C J Godec; R S Verma
Journal:  J Mol Med (Berl)       Date:  1996-08       Impact factor: 4.599

3.  The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.

Authors:  W M Stadler; O I Olopade
Journal:  Urol Res       Date:  1996

4.  Diaphyseal medullary stenosis with malignant fibrous histiocytoma: a hereditary bone dysplasia/cancer syndrome maps to 9p21-22.

Authors:  J A Martignetti; R J Desnick; E Aliprandis; K I Norton; P Hardcastle; S Nade; B D Gelb
Journal:  Am J Hum Genet       Date:  1999-03       Impact factor: 11.025

5.  The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine.

Authors:  I A Sokolova; K C Halling; R B Jenkins; H M Burkhardt; R G Meyer; S A Seelig; W King
Journal:  J Mol Diagn       Date:  2000-08       Impact factor: 5.568

6.  Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification.

Authors:  Joanne S Aveyard; Margaret A Knowles
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

Review 7.  Hepatocarcinogenesis in rodents and humans.

Authors:  T Kitagawa; K Miyasaka; H Kanda; H Yasui; O Hino
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

Review 8.  Molecular cytogenetic quantitation of gains and losses of genetic material from human gliomas.

Authors:  B G Feuerstein; G Mohapatra
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

9.  A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer.

Authors:  Tomas Bonome; Douglas A Levine; Joanna Shih; Mike Randonovich; Cindy A Pise-Masison; Faina Bogomolniy; Laurent Ozbun; John Brady; J Carl Barrett; Jeff Boyd; Michael J Birrer
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

10.  Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma.

Authors:  Anton H N Hopman; Miriam A F Kamps; Ernst J M Speel; Rene F M Schapers; Guido Sauter; Frans C S Ramaekers
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.